Pacira BioSciences, Inc. PCRX
36.48 USD 0.00 (+0.00%)
Regular-session close
36.48 0.00 0.00%
After hours · Nov 16, 4:00 PM ET
36.48 Day range 36.49
18.80 52-week range 36.67
- YTD
- +40.96%
- 1 year
- +53.41%
News
prnewswire.com Viatris Completes Acquisition of Pacira BioSciences PITTSBURGH, Nov. 17, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that it has completed its acquisition of Pacira BioSciences, Inc.…
prnewswire.com Ingram Micro Holding Set to Join S&P SmallCap 600 NEW YORK, Nov. 11, 2026 /PRNewswire/ -- Ingram Micro Holding Corp. (NYSE: INGM) will replace Pacira BioSciences Inc. (NASD: PCRX) in the S&P SmallCap 600 effective prior to the opening of trading on…benzinga.com Ingram Micro To Replace Pacira Biosciences In the S&P SmallCap 600 Effective Prior To The Opening Of Trading On Tuesday, November 17 https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20261111-1485671/1485671_pcrx6.pdf
fool.com Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT? One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.
businesswire.com Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…benzinga.com Pacira BioSciences Withdraws 2026 Guidance Pending Proposed Merger With Viatris As previously disclosed, on October 8, 2026, Pacira BioSciences, Inc., a Delaware corporation (the "Company" or "Pacira"), entered into the Agreement and Plan of Merger (the "Merger Agreement")
prnewswire.com Viatris Reports Third-Quarter 2026 Financial Results Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in…
globenewswire.com INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU? NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and…
prnewswire.com Are BWIN, LFCR, PCRX Obtaining Fair Deals for their Shareholders? /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
prnewswire.com INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU? /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for
businesswire.com PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash. Halper…benzinga.com Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to
prnewswire.com Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc. PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary…
gurufocus.com Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders? Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 12, 2026Insiders may stand to receive substantial financial bene
prnewswire.com Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders? /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
businesswire.com Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
gurufocus.com SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX) SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)PR NewswireNEW YORK, Oct. 11, 2026NEW YORK, Oc
prnewswire.com SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX) NEW YORK, Oct. 11, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is…
zacks.com Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
newsfilecorp.com SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX) Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Pacira BioSciences,…
gurufocus.com PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC. PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.PR NewswireMILWAUKEE, Oct. 8, 2026PCRX shareholders will rec
prnewswire.com PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC. PCRX shareholders will receive just $36.50 per share in cash, representing an aggregate equity value of $1.65 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and…
schaeffersresearch.com 2 Stocks Drawing Bearish Options Activity Today Options traders are taking a bearish stance on two stocks attracting unusual volume today: Pacira BioSciences Inc (NASDAQ:PCRX) and Ring Energy Inc (NYSEAMERICAN:REI).
